ALFA FinderNSE filing, NSE: KILITCH. Summary written from the filing by ALFA Finder's alert engine.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹200.61
- Market cap
- ₹701.4 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 29.1×Sector 43.8×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Acquisition Worth ₹56.82 Cr
Kilitch Drugs rectified its October 22 board outcome on converting debt into material subsidiary KEB shares. Corrected terms: 1,66,471 shares at Rs 3,413.23 each, about Rs 56.82 Cr.
- Value
- ₹56.82 Cr
Kilitch Drugs(I) Q2 FY27 Results: Net Profit ₹1.4 Cr, Down 82.5% YoY
Kilitch Drugs(I) Ltd reported revenue from operations of ₹50.2 Cr (+2.7% YoY) and net profit of ₹1.4 Cr (-82.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.4 Cr · -82.5% YoY
Kilitch Drugs(I) Board Meeting Date
Kilitch Drugs will hold a board meeting on 6 November 2026 to consider unaudited quarterly and half-year results. The trading window stays closed until 48 hours after disclosure.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs(I) Merger & Restructuring Worth ₹131.6 Cr
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
- Value
- ₹131.6 Cr
Kilitch Drugs(I) Merger & Restructuring Worth ₹120.8 Cr
Kilitch Drugs will divest its 100% stake in subsidiary Kilitch Estro Biotech PLC for USD 12.855 million (approx. ₹120.84 Crore).
- Value
- ₹120.8 Cr
- From
- HarmeeCare Pharmaceuticals
Other annual general meeting announcements
All →Abans Enterprises Annual General Meeting
Abans Enterprises seeks postal ballot approval to liquidate step-down subsidiary Abans Gems and Jewels Trading FZC. It also seeks approval for a material related party transaction.
Indo Borax & Chemicals Annual General Meeting
Indo Borax & Chemicals approved a Special Resolution under Section 180(1)(a) to provide security for company borrowings via postal ballot. Promoters held 100% of votes polled, and the resolution passed with 100.00% in favour.
Kesoram Industries Annual General Meeting
Kesoram Industries disclosed postal ballot results approving six special resolutions, including appointment of four independent directors, a non-executive director and a managing director. The scrutinizer's report was issued on 11 November 2026.
Indian Metals & Ferro Alloys Annual General Meeting
Indian Metals approved Partha Satpathy as Non-Executive Independent Director for three years via postal ballot. The special resolution was passed on November 12, 2026.
Oriana Power Annual General Meeting
Oriana Power's postal ballot approved material related party transactions with Oriana Usolar Joint Venture Private Limited, with 99.7196% of votes cast in favour. The resolution was deemed passed on November 8, 2026.
BGR Energy Systems Annual General Meeting
BGR Energy issued a postal ballot notice seeking member approval for a Whole-Time Director appointment, authorised capital increase, and a director remuneration revision. E-voting runs 13 November to 12 December 2026.